These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7905082)

  • 1. Poor metabolisers of nicotine and CYP2D6 polymorphism.
    Cholerton S; Arpanahi A; McCracken N; Boustead C; Taber H; Johnstone E; Leathart J; Daly AK; Idle JR
    Lancet; 1994 Jan; 343(8888):62-3. PubMed ID: 7905082
    [No Abstract]   [Full Text] [Related]  

  • 2. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
    Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
    J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
    Messina ES; Tyndale RF; Sellers EM
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.
    Nebert DW
    Cancer Cells; 1991 Mar; 3(3):93-6. PubMed ID: 2054261
    [No Abstract]   [Full Text] [Related]  

  • 5. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
    Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
    Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2A6 polymorphism, nicotine, and environmental nitrosamines.
    Idle JR
    Lancet; 1999 Jun; 353(9169):2073. PubMed ID: 10376647
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack association between schizophrenia and the CYP2D6 gene polymorphisms.
    Pirmohamed M; Wild MJ; Kitteringham NR; O'Brien K; Buchan IE; Back DJ; Park BK
    Am J Med Genet; 1996 Apr; 67(2):236-7. PubMed ID: 8723057
    [No Abstract]   [Full Text] [Related]  

  • 8. Arg296 to Cys296 polymorphism in exon 6 of cytochrome P-450-2D6 (CYP2D6) is not associated with multiple system atrophy.
    Bandmann O; Wenning GK; Quinn NP; Harding AE
    J Neurol Neurosurg Psychiatry; 1995 Nov; 59(5):557. PubMed ID: 8530951
    [No Abstract]   [Full Text] [Related]  

  • 9. Familial Parkinson's disease and polymorphism at the CYP2D6 locus.
    Mazzetti P; Le Guern E; Bonnet AM; Vidailhet M; Brice A; Agid Y
    J Neurol Neurosurg Psychiatry; 1994 Jul; 57(7):871-2. PubMed ID: 8021689
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytochrome P450dbl phenotypes in malignant and benign breast disease.
    Pontin JE; Hamed H; Fentiman IS; Idle JR
    Eur J Cancer; 1990; 26(7):790-2. PubMed ID: 2145896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction.
    Armstrong M; Idle JR; Daly AK
    Hum Genet; 1993 Jul; 91(6):616-7. PubMed ID: 8340116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of debrisoquine hydroxylation phenotypes.
    Wolf CR; Moss JE; Miles JS; Gough AC; Spurr NK
    Lancet; 1990 Dec; 336(8728):1452-3. PubMed ID: 1978915
    [No Abstract]   [Full Text] [Related]  

  • 13. [Genetic polymorphism of drug metabolizing enzymes].
    Yokoi T; Kamataki T
    Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
    [No Abstract]   [Full Text] [Related]  

  • 14. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
    Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
    Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan.
    Persson K; Sjöström S; Sigurdardottir I; Molnár V; Hammarlund-Udenaes M; Rane A
    Br J Clin Pharmacol; 1995 Feb; 39(2):182-6. PubMed ID: 7742159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Individualization of drug therapy and pharmacogenetics].
    Yamamoto I; Azuma J
    Nihon Rinsho; 1998 Mar; 56(3):579-83. PubMed ID: 9549339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
    Dahl ML
    Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of phenotype and genotype for CYP2D6.
    McLeod HL
    Clin Pharmacol Ther; 1994 Oct; 56(4):463-4. PubMed ID: 7955809
    [No Abstract]   [Full Text] [Related]  

  • 19. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
    Ashforth EI; Palmer JL; Bye A; Bedding A
    Br J Clin Pharmacol; 1994 Apr; 37(4):389-91. PubMed ID: 8018461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides.
    Botsch S; Heinkele G; Meese CO; Eichelbaum M; Kroemer HK
    Eur J Clin Pharmacol; 1994; 46(2):133-5. PubMed ID: 8039531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.